OncoPep, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2010-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.oncopep.com
Phase 2 Study to Evaluate PVX-410 + Pembrolizumab + Chemotherapy for Metastatic, PD-L1+ Triple-Negative Breast Cancer
Phase 2
Not yet recruiting
- Conditions
- Metastatic Triple-Negative Breast Carcinoma
- Interventions
- First Posted Date
- 2020-11-18
- Last Posted Date
- 2022-04-20
- Lead Sponsor
- OncoPep, Inc.
- Target Recruit Count
- 53
- Registration Number
- NCT04634747
Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma
Phase 1
Completed
- Conditions
- Smoldering Multiple Myeloma
- Interventions
- Biological: PVX-410
- First Posted Date
- 2012-10-31
- Last Posted Date
- 2016-09-28
- Lead Sponsor
- OncoPep, Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT01718899
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
🇺🇸Illinois Cancer Specialists, Niles, Illinois, United States
© Copyright 2025. All Rights Reserved by MedPath